专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070117827A1 Compositions for affecting weight loss 审中-公开
标题翻译：用于影响减肥的组合物
公开(公告)号：US20070117827A1
公开(公告)日：2007-05-24
申请号：US11492685
申请日：2006-07-24
申请人： Gary Tollefson , Anthony McKinney , Michelle Higgin , John McCall
发明人： Gary Tollefson , Anthony McKinney , Michelle Higgin , John McCall
IPC分类号： A61K31/485 , A61K31/165
CPC分类号： A61K31/137 , A61K31/138 , A61K31/165 , A61K31/485 , A61K45/06 , A61K2300/00
摘要： Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a metabolite of naltrexone, such as 6-β-naltrexol or a prodrug of a naltrexone metabolite, and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) and/or a melanocortin 4 receptor (MC4-R), and/or increases the concentration of α-MSH in the central nervous system. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity with a metabolite of naltrexone, such as 6-β-naltrexol or a prodrug of a naltrexone metabolite, and treating that individual to enhance α-MSH activity, e.g., by administration of a second compound causes increased agonism of MC3-R and/or MC4-R, and/or increases the concentration of α-MSH in the central nervous system.
摘要翻译：公开了用于影响体重减轻的组合物，其包含第一化合物和第二化合物，其中第一化合物是纳曲酮的代谢物，例如6-β-纳曲酮或纳曲酮代谢物的前药，并且所述第二化合物导致增加的激动黑皮质素3受体（MC3-R）和/或黑皮质素4受体（MC4-R），和/或增加中枢神经系统中α-MSH的浓度。还公开了影响体重减轻，增加能量消耗，增加个体饱腹感或抑制个体食欲的方法，其包括确定有需要的个体，并用纳曲酮代谢物治疗该个体以拮抗阿片受体活性，作为6-β-纳曲酮或纳曲酮代谢物的前药，并且例如通过施用第二化合物治疗该个体以增强α-MSH活性，导致MC3-R和/或MC4-R的激动作用增加，和/或增加中枢神经系统中α-MSH的浓度。

2. 发明申请

US20120093889A1 LAYERED PHARMACEUTICAL FORMULATIONS 有权
标题翻译：层状药物制剂
公开(公告)号：US20120093889A1
公开(公告)日：2012-04-19
申请号：US13330395
申请日：2011-12-19
申请人： Anthony McKinney , Gary Tollefson , Eckard Weber , Rick Soltero
发明人： Anthony McKinney , Gary Tollefson , Eckard Weber , Rick Soltero
IPC分类号： A61K9/00 , A61K31/485 , A61K31/423 , A61P3/04
CPC分类号： A61K9/209 , A61K9/0002 , A61K9/2018 , A61K9/2054 , A61K31/137 , A61K31/138 , A61K31/155 , A61K31/35 , A61K31/357 , A61K31/42 , A61K31/423 , A61K31/485 , A61K31/551 , A61K31/5513 , A61K45/06 , A61K47/26 , A61K2300/00
摘要： In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.
摘要翻译：在一个实施方案中，分层药物制剂包含两个或更多个药物层和设置在两个或更多个药物层中的至少两个之间的中间层，所述中间层被配置为在体内溶解，从而使两个或更多个药物层基本上保持完好。在一个实施方案中，至少一个药物层中的活性药物成分选自安非他酮，唑尼沙胺，纳曲酮，托吡酯，芬特明，二甲双胍，奥氮平和氟西汀。

3. 发明申请

US20080113026A1 LAYERED PHARMACEUTICAL FORMULATIONS 有权
标题翻译：层状药物制剂
公开(公告)号：US20080113026A1
公开(公告)日：2008-05-15
申请号：US11937421
申请日：2007-11-08
申请人： Anthony McKinney , Gary Tollefson , Eckard Weber , Rick Soltero
发明人： Anthony McKinney , Gary Tollefson , Eckard Weber , Rick Soltero
IPC分类号： A61K9/24
CPC分类号： A61K9/209 , A61K9/0002 , A61K9/2018 , A61K9/2054 , A61K31/137 , A61K31/138 , A61K31/155 , A61K31/35 , A61K31/357 , A61K31/42 , A61K31/423 , A61K31/485 , A61K31/551 , A61K31/5513 , A61K45/06 , A61K47/26 , A61K2300/00
摘要： In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.
摘要翻译：在一个实施方案中，分层药物制剂包含两个或更多个药物层和设置在两个或更多个药物层中的至少两个之间的中间层，所述中间层被配置为在体内溶解，从而使两个或更多个药物层基本上保持完好。在一个实施方案中，至少一个药物层中的活性药物成分选自安非他酮，唑尼沙胺，纳曲酮，托吡酯，芬特明，二甲双胍，奥氮平和氟西汀。

4. 发明申请

US20070185084A1 COMPOSITIONS OF AN ANTICONVULSANT AND METHODS OF USING THE SAME FOR REVERSING WEIGHT GAIN 审中-公开
标题翻译：抗生素的组合物和使用相同方法反转重量增益
公开(公告)号：US20070185084A1
公开(公告)日：2007-08-09
申请号：US11622363
申请日：2007-01-11
申请人： Anthony McKinney , Gary Tollefson , Michael Cowley
发明人： Anthony McKinney , Gary Tollefson , Michael Cowley
IPC分类号： A61K31/551
CPC分类号： A61K45/06 , A61K31/135 , A61K31/137 , A61K31/20 , A61K31/423 , A61K31/498 , A61K31/5513 , A61K31/554 , A61K33/00 , A61K2300/00
摘要： Disclosed are compositions for reversing weight gain comprising a first compound and a second compound, where the first compound is an anticonvulsant and the second compound is a psychotherapeutic agent.
摘要翻译：公开了用于逆转体重增加的组合物，其包含第一化合物和第二化合物，其中第一化合物是抗惊厥药，第二化合物是心理治疗剂。

5. 发明申请

US20070128298A1 Compositions and methods for increasing insulin sensitivity 有权
标题翻译：用于增加胰岛素敏感性的组合物和方法
公开(公告)号：US20070128298A1
公开(公告)日：2007-06-07
申请号：US11602571
申请日：2006-11-21
申请人： Michael Cowley , Anthony McKinney , Gary Tollefson
发明人： Michael Cowley , Anthony McKinney , Gary Tollefson
IPC分类号： A61K31/554 , A61K31/5513 , A61K31/551 , A61K31/55 , A61K31/445 , A61K31/519 , A61K31/5415
CPC分类号： A61K38/28 , A61K31/135 , A61K31/137 , A61K31/138 , A61K31/35 , A61K31/357 , A61K31/423 , A61K31/445 , A61K31/4525 , A61K31/485 , A61K31/519 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/554 , A61K31/7048 , A61K45/06 , A61K2300/00
摘要： Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.
摘要翻译：用于治疗血糖状况的方法和组合物包括鉴定合适的受试者并施用有效量的含有阿片样物质拮抗剂，抗惊厥药和精神治疗药物中的一种或多种的组合物。组合物可以包括胰岛素。在一些实施方案中，这些方法和组合物可用于调节血糖水平。在优选的实施方案中，这些方法和组合物可用于增加受试者对胰岛素的敏感性。

6. 发明授权

US08722085B2 Methods for administering weight loss medications 有权
标题翻译：减肥药物的给药方法
公开(公告)号：US08722085B2
公开(公告)日：2014-05-13
申请号：US12838364
申请日：2010-07-16
申请人： Anthony McKinney , Gary Tollefson , Eckard Weber , Rick Soltero
发明人： Anthony McKinney , Gary Tollefson , Eckard Weber , Rick Soltero
IPC分类号： A61K9/20 , A61K31/415 , A61K31/137 , A61K31/439 , A61K31/35 , A61K31/551 , A61P3/04
CPC分类号： A61K9/209 , A61J1/035 , A61J7/04 , A61J7/0454 , A61K31/135 , A61K31/137 , A61K31/138 , A61K31/35 , A61K31/42 , A61K31/423 , A61K31/485 , A61K31/551 , A61K31/5513 , A61K31/7048 , A61K45/06 , B65D75/36 , A61K2300/00
摘要： Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.
摘要翻译：用于使用包括具有第一药物和第二药物的第一单位剂量的单位剂量包装的药物的给药方法和系统，具有第一药物和第二药物的第二单位剂量，其中第二单位剂量包括不同的第二药物的量比第一单位剂量和单位剂量包装被配置为保持第一单位剂量和第二单位剂量。在优选的实施方案中，所述方法和系统用于施用减肥药物。

7. 发明申请

US20080110792A1 METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS 审中-公开
标题翻译：管理重量损失药物的方法
公开(公告)号：US20080110792A1
公开(公告)日：2008-05-15
申请号：US11937367
申请日：2007-11-08
申请人： Anthony McKinney , Gary Tollefson , Eckard Weber , Rick Soltero
发明人： Anthony McKinney , Gary Tollefson , Eckard Weber , Rick Soltero
IPC分类号： B65D83/04 , B65D85/42
CPC分类号： A61K9/209 , A61J1/035 , A61J7/04 , A61J7/0454 , A61K31/135 , A61K31/137 , A61K31/138 , A61K31/35 , A61K31/42 , A61K31/423 , A61K31/485 , A61K31/551 , A61K31/5513 , A61K31/7048 , A61K45/06 , B65D75/36 , A61K2300/00
摘要： Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.
摘要翻译：用于使用包括具有第一药物和第二药物的第一单位剂量的单位剂量包装的药物的给药方法和系统，具有第一药物和第二药物的第二单位剂量，其中第二单位剂量包括不同的第二药物的量比第一单位剂量和单位剂量包装被配置为保持第一单位剂量和第二单位剂量。在优选的实施方案中，所述方法和系统用于施用减肥药物。

8. 发明申请

US20070281021A1 SUSTAINED RELEASE FORMULATION OF NALTREXONE 有权
标题翻译：持续释放NALTREXONE的配方
公开(公告)号：US20070281021A1
公开(公告)日：2007-12-06
申请号：US11757773
申请日：2007-06-04
申请人： Anthony McKinney , Gary Tollefson , Richard Soltero , Thea Dunzo
发明人： Anthony McKinney , Gary Tollefson , Richard Soltero , Thea Dunzo
IPC分类号： A61K31/485 , A61K9/22
CPC分类号： A61K31/485 , A61K9/0053 , A61K9/20 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/209 , A61K31/12 , A61K31/137
摘要： A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.
摘要翻译：提供了纳曲酮或其药学上可接受的盐的缓释口服剂型。口服剂型可以与另一种化合物一起施用。口服剂型的给药可以减少副作用，其可能是至少部分归因于减肥治疗的副作用。可以施用口服剂型以治疗体重减轻状况。

9. 发明授权

US08318788B2 Layered pharmaceutical formulations 有权
公开(公告)号：US08318788B2
公开(公告)日：2012-11-27
申请号：US13330395
申请日：2011-12-19
申请人： Anthony McKinney , Gary Tollefson , Eckard Weber , Rick Soltero
发明人： Anthony McKinney , Gary Tollefson , Eckard Weber , Rick Soltero
IPC分类号： A61K9/00 , A61K31/485 , A61K31/423 , A61P3/04
CPC分类号： A61K9/209 , A61K9/0002 , A61K9/2018 , A61K9/2054 , A61K31/137 , A61K31/138 , A61K31/155 , A61K31/35 , A61K31/357 , A61K31/42 , A61K31/423 , A61K31/485 , A61K31/551 , A61K31/5513 , A61K45/06 , A61K47/26 , A61K2300/00
摘要： In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.

10. 发明授权

US08088786B2 Layered pharmaceutical formulations 有权
标题翻译：分层药物制剂
公开(公告)号：US08088786B2
公开(公告)日：2012-01-03
申请号：US11937421
申请日：2007-11-08
申请人： Anthony McKinney , Gary Tollefson , Eckard Weber , Rick Soltero
发明人： Anthony McKinney , Gary Tollefson , Eckard Weber , Rick Soltero
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K9/209 , A61K9/0002 , A61K9/2018 , A61K9/2054 , A61K31/137 , A61K31/138 , A61K31/155 , A61K31/35 , A61K31/357 , A61K31/42 , A61K31/423 , A61K31/485 , A61K31/551 , A61K31/5513 , A61K45/06 , A61K47/26 , A61K2300/00
摘要： In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.
摘要翻译：在一个实施方案中，分层药物制剂包含两个或更多个药物层和设置在两个或更多个药物层中的至少两个之间的中间层，所述中间层被配置为在体内溶解，从而使两个或更多个药物层基本上保持完好。在一个实施方案中，至少一个药物层中的活性药物成分选自安非他酮，唑尼沙胺，纳曲酮，托吡酯，芬特明，二甲双胍，奥氮平和氟西汀。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式